Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH Repurposing Of Failed Compounds Could Begin Soon; NCATS Plans Pilots

Executive Summary

The National Center for Advancing Translational Science soon may have an agreement with one or more firms to allow research to test abandoned compounds for new uses, NIH Deputy Director for Science, Outreach and Policy Kathy Hudson says. NIH has sought, and will continue to seek, industry input on where NCATS should put its efforts to speed translation of drugs from the bench to the market, she notes.

You may also be interested in...



FDA, NIH Devise Regulatory Research Agenda, Look For Financing

The budget sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Sciences Director Christopher Austin notes. The Institute of Medicine recommends more collaborations to strengthen the Clinical and Translational Science Awards program.

FDA, NIH Devise Regulatory Research Agenda, Look For Financing

The budget sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Sciences Director Christopher Austin notes. The Institute of Medicine recommends more collaborations to strengthen the Clinical and Translational Science Awards program.

FDA, NIH Devise Regulatory Research Agenda, Look For Financing

The sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Sciences Director Christopher Austin noted during a June 25 teleconference to discuss Institute of Medicine recommendations for strengthening the Clinical and Translational Science Awards program.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS054068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel